Canada's Cipher Pharmaceuticals Q4 net income rises

Cipher Pharmaceuticals

12/03/2026 21:12

Overview

Canada specialty pharma firm's Q4 net income rose yr/yr

Adjusted EBITDA for Q4 rose 40% yr/yr

Outlook

Cipher expects to drive market share growth for Natroba™ in the U.S. anti-parasitic market

Company aims to obtain Health Canada approval for Natroba™ and commercialize it in Canada

Cipher plans to pursue acquisitions and out-licensing Natroba™ globally in regions with high unmet need

Result Drivers

NATROBA PERFORMANCE - Co said additional operating income from U.S. business led by Natroba drove Q4 results

HIGHER GROSS MARGIN - Gross margin rose to 81%, driven by absence of prior-year non-cash inventory adjustments and strong Natroba margins

Company press release: ID:nCNW2lbGMa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
$13.3 mln
Q4 Adjusted EBITDA
Beat
$6.97 mln
$5.87 mln (2 Analysts)
Q4 EBITDA
$6.53 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Cipher Pharmaceuticals Inc is C$19.00, about 31.6% above its March 11 closing price of C$14.44

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)